Episode Details
Back to EpisodesNurExone Biologic's Revolutionary Approach to Nerve Regeneration
Season 2
Episode 102
Published 5 months, 3 weeks ago
Description
In this episode of WTR Healthcare Happenings, host Tim Gerdeman and WTR’s Robert Sassoon speak with Dr. Lior Shaltiel, CEO of NuroExone Biologic (OTCQB: NRXBF/TSXV: NRX), an early-stage regenerative therapy developer, along with the company’s Founder, VP Business Development & Active Chairman, Yoram Drucker to talk about NurExone's novel regenerative exosome-based therapies development pipeline for central nervous system injuries, led by spinal cord and optic nerve injuries, both multi-billion-dollar markets. Our conversation covers key differentiators from other developments targeting those indications, the company's path towards clinical trials, and its financial capabilities and strategy to advance its development programs.